Great interest in DrugLog® at Drug Diversion conference
The IHFDA is holding its annual conference in Orlando September 23-25. It is aimed at decision makers and leading pharmacists in the health care sector who work with Drug Diversion prevention programs. The need to control returned narcotics from the OR is increasing and both delegates and representatives from major multinational companies have shown great interest in DrugLog®.
The International Health Facility Diversion Association (IHFDA) holds its annual conference in Orlando September 23-25 and attracts approximately 200 delegates from US hospitals. It is aimed at decision makers and leading pharmacists in the health care sector who work with programs to prevent Drug Diversion. The need to control returns from the OR is increasing. The number of doses of narcotic drugs that are being diverted has increased from 21 million in 2017 to 48 million in 2018. The US authorities place increasing demands on the medical establishment to establish a so-called Drug Diversion Prevention program. Such a program includes control of returns as an increasingly important part.
Mats Högberg, CEO, comments: “The IHFDA is a small but very important conference because all participants have the task of establishing the Drug Diversion Program. At the same time, all players in the industry are present, so it gives us good opportunities to discuss potential partnerships. We note a great deal of interest from both customers and other players in the industry. With DrugLog we have a proven tool with great development potential, something that is viewed with great interest from major players who have complete solutions in the management of narcotic drugs but who do not have a reliable instrument for analyzing returns. The conference has already provided a large number of interesting contacts who will keep our new sales manager here in the US, Jeff Marton, busy for a long time to come.”
Pharmacolog is specialized in developing systems and solutions for more effective and safer use of intravenous drugs. The company’s first product, DrugLog®, enables a nurse or pharmacist to quickly and easily verify that an injectable drug has the right identity and concentration. Pharmacolog’s long-term vision is an individually optimized medication for each individual patient, considering all available parameters in the control and distribution of the drug. Further information regarding the company is available at http://www.pharmacolog.com. The company’s Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through CA@mangold.se.